Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 501

1.

Differentiation syndrome in acute promyelocytic leukaemia.

Stahl M, Tallman MS.

Br J Haematol. 2019 Aug 13. doi: 10.1111/bjh.16151. [Epub ahead of print] Review.

PMID:
31410848
2.

The Role of Abnormal Hemostasis and Fibrinolysis in Morbidity and Mortality of Acute Promyelocytic Leukemia.

Kwaan HC, Weiss I, Tallman MS.

Semin Thromb Hemost. 2019 Aug 1. doi: 10.1055/s-0039-1693478. [Epub ahead of print]

PMID:
31370070
3.

Pentostatin, Cyclophosphamide, and Rituximab Followed by Alemtuzumab for Relapsed or Refractory Chronic Lymphocytic Leukemia: A Phase 2 Trial of the ECOG-Acrin Cancer Research Group (E2903).

Kempin S, Sun Z, Kay NE, Paietta EM, Mazza JJ, Ketterling RP, Frankfurt O, Claxton DF, Saltzman JN, Srkalovic G, Callander NS, Gross G, Tallman MS.

Acta Haematol. 2019 Jul 23:1-9. doi: 10.1159/000500164. [Epub ahead of print]

PMID:
31336367
4.

Immunotherapy for acute myeloid leukemia: from allogeneic stem cell transplant to novel therapeutics.

Knorr DA, Goldberg AD, Stein EM, Tallman MS.

Leuk Lymphoma. 2019 Jul 23:1-13. doi: 10.1080/10428194.2019.1639167. [Epub ahead of print]

PMID:
31335250
5.

Combining gene mutation with gene expression analysis improves outcomes prediction in acute promyelocytic leukemia.

Lucena-Araujo AR, Coelho-Silva JL, Pereira-Martins DA, Silveira DR MD, Koury LCA, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Nunes EC, Fagundes EM, Gloria AB, Kerbauy FR, Chauffaille ML, Bendit I, Rocha V, Keating A, Tallman MS, Ribeiro RC, Dillon R, Ganser A, Löwenberg B, Valk P, Lo Coco F, Sanz MA, Berliner N, Rego EM.

Blood. 2019 Jul 10. pii: blood.2019000239. doi: 10.1182/blood.2019000239. [Epub ahead of print]

PMID:
31292112
6.

Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmark.

Taylor J, Haddadin M, Upadhyay VA, Grussie E, Mehta-Shah N, Brunner AM, Louissaint A Jr, Lovitch SB, Dogan A, Fathi AT, Stone RM, Tallman MS, Rampal RK, Neuberg DS, Stevenson KE, Horwitz SM, Lane AA.

Blood. 2019 Aug 22;134(8):678-687. doi: 10.1182/blood.2019001144. Epub 2019 Jun 26.

PMID:
31243042
7.

Myoclonic jerks complicating treatment of acute promyelocytic leukemia: case report and literature review.

Rhee JY, Tremblay D, Chan AM, Tallman MS, Mascarenhas J.

Blood Adv. 2019 Jun 25;3(12):1854-1857. doi: 10.1182/bloodadvances.2019000249. No abstract available.

8.

Antibody-based therapy in acute leukemia - beware the risks.

Stahl M, Tallman MS.

Leuk Lymphoma. 2019 Jul;60(7):1608-1609. doi: 10.1080/10428194.2019.1608535. Epub 2019 Jun 17. No abstract available.

PMID:
31204877
9.

Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.

Tallman MS, Wang ES, Altman JK, Appelbaum FR, Bhatt VR, Bixby D, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Hall AC, Jacoby M, Lancet J, LeBlanc TW, Mannis G, Marcucci G, Martin MG, Mims A, O'Donnell MR, Olin R, Peker D, Perl A, Pollyea DA, Pratz K, Prebet T, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wieduwilt M, Gregory KM; OCN, Hammond L, Ogba N.

J Natl Compr Canc Netw. 2019 Jun 1;17(6):721-749. doi: 10.6004/jnccn.2019.0028.

PMID:
31200351
10.

Molecular and cytogenetic characteristics of myeloid malignancies following luminal gastrointestinal cancer.

Epstein-Peterson ZD, Devlin SM, Stein EM, Klimek VM, Saltz LB, Tallman MS.

Leuk Res. 2019 Jul;82:19-23. doi: 10.1016/j.leukres.2019.05.010. Epub 2019 May 24.

PMID:
31151028
11.

Rational Targeting of Cooperating Layers of the Epigenome Yields Enhanced Therapeutic Efficacy against AML.

Duy C, Teater M, Garrett-Bakelman FE, Lee TC, Meydan C, Glass JL, Li M, Hellmuth JC, Mohammad HP, Smitheman KN, Shih AH, Abdel-Wahab O, Tallman MS, Guzman ML, Muench D, Grimes HL, Roboz GJ, Kruger RG, Creasy CL, Paietta EM, Levine RL, Carroll M, Melnick AM.

Cancer Discov. 2019 Jul;9(7):872-889. doi: 10.1158/2159-8290.CD-19-0106. Epub 2019 May 10.

PMID:
31076479
12.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS.

Leukemia. 2019 May 9. doi: 10.1038/s41375-019-0477-x. [Epub ahead of print]

PMID:
31073153
13.

Allogeneic hematopoietic cell transplantation improves outcome of adults with t(6;9) acute myeloid leukemia - results from an international collaborative study.

Kayser S, Hills RK, Luskin MR, Brunner AM, Terré C, Westermann J, Menghrajani K, Shaw C, Baer MR, Elliott MA, Perl AE, Ráčil Z, Mayer J, Zak P, Szotkowski T, de Botton S, Grimwade D, Mayer K, Walter RB, Krämer A, Burnett AK, Ho AD, Platzbecker U, Thiede C, Ehninger G, Stone RM, Röllig C, Tallman MS, Estey EH, Müller-Tidow C, Russell NH, Schlenk RF, Levis MJ.

Haematologica. 2019 Apr 19. pii: haematol.2018.208678. doi: 10.3324/haematol.2018.208678. [Epub ahead of print]

14.

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

Pollyea DA, Tallman MS, de Botton S, Kantarjian HM, Collins R, Stein AS, Frattini MG, Xu Q, Tosolini A, See WL, MacBeth KJ, Agresta SV, Attar EC, DiNardo CD, Stein EM.

Leukemia. 2019 Apr 9. doi: 10.1038/s41375-019-0472-2. [Epub ahead of print]

PMID:
30967620
15.

Exciting Times in Acute Myeloid Leukemia.

Tallman MS.

Semin Hematol. 2019 Apr;56(2):83. doi: 10.1053/j.seminhematol.2019.03.002. No abstract available.

PMID:
30926094
17.

The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia.

Yeshurun M, Weisdorf D, Rowe JM, Tallman MS, Zhang MJ, Wang HL, Saber W, de Lima M, Sandmaier BM, Uy G, Kamble RT, Cairo MS, Cooper BW, Cahn JY, Ganguly S, Camitta B, Verdonck LF, Dandoy C, Diaz MA, Savani BN, George B, Liesveld J, McGuirk J, Byrne M, Grunwald MR, Drobyski WR, Pulsipher MA, Abdel-Azim H, Prestidge T, Wieduwilt MJ, Martino R, Norkin M, Beitinjaneh A, Seo S, Nishihori T, Wirk B, Frangoul H, Bashey A, Mori S, Marks DI, Bachanova V.

Blood Adv. 2019 Feb 26;3(4):670-680. doi: 10.1182/bloodadvances.2018027003.

18.

Management of acute promyelocytic leukemia: updated recommendations from an expert panel of the European LeukemiaNet.

Sanz MA, Fenaux P, Tallman MS, Estey EH, Löwenberg B, Naoe T, Lengfelder E, Döhner H, Burnett AK, Chen SJ, Mathews V, Iland H, Rego E, Kantarjian H, Adès L, Avvisati G, Montesinos P, Platzbecker U, Ravandi F, Russell NH, Lo-Coco F.

Blood. 2019 Apr 11;133(15):1630-1643. doi: 10.1182/blood-2019-01-894980. Epub 2019 Feb 25. Review.

19.

BRAF in the cross-hairs.

Geyer MB, Abdel-Wahab O, Tallman MS.

Expert Rev Hematol. 2019 Mar;12(3):183-193. doi: 10.1080/17474086.2019.1583553. Epub 2019 Feb 26.

PMID:
30782032
20.

The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900).

Medeiros BC, Othus M, Tallman MS, Sun Z, Fernandez HF, Rowe JM, Lazarus HM, Appelbaum FR, Luger SM, Litzow MR, Erba HP.

Leuk Res. 2019 Mar;78:29-33. doi: 10.1016/j.leukres.2019.01.007. Epub 2019 Jan 17.

21.

A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403.

Stock W, Luger SM, Advani AS, Yin J, Harvey RC, Mullighan CG, Willman CL, Fulton N, Laumann KM, Malnassy G, Paietta E, Parker E, Geyer S, Mrózek K, Bloomfield CD, Sanford B, Marcucci G, Liedtke M, Claxton DF, Foster MC, Bogart JA, Grecula JC, Appelbaum FR, Erba H, Litzow MR, Tallman MS, Stone RM, Larson RA.

Blood. 2019 Apr 4;133(14):1548-1559. doi: 10.1182/blood-2018-10-881961. Epub 2019 Jan 18.

PMID:
30658992
22.

PAX5-driven subtypes of B-progenitor acute lymphoblastic leukemia.

Gu Z, Churchman ML, Roberts KG, Moore I, Zhou X, Nakitandwe J, Hagiwara K, Pelletier S, Gingras S, Berns H, Payne-Turner D, Hill A, Iacobucci I, Shi L, Pounds S, Cheng C, Pei D, Qu C, Newman S, Devidas M, Dai Y, Reshmi SC, Gastier-Foster J, Raetz EA, Borowitz MJ, Wood BL, Carroll WL, Zweidler-McKay PA, Rabin KR, Mattano LA, Maloney KW, Rambaldi A, Spinelli O, Radich JP, Minden MD, Rowe JM, Luger S, Litzow MR, Tallman MS, Racevskis J, Zhang Y, Bhatia R, Kohlschmidt J, Mrózek K, Bloomfield CD, Stock W, Kornblau S, Kantarjian HM, Konopleva M, Evans WE, Jeha S, Pui CH, Yang J, Paietta E, Downing JR, Relling MV, Zhang J, Loh ML, Hunger SP, Mullighan CG.

Nat Genet. 2019 Feb;51(2):296-307. doi: 10.1038/s41588-018-0315-5. Epub 2019 Jan 14.

23.

Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL.

Wendorff AA, Quinn SA, Rashkovan M, Madubata CJ, Ambesi-Impiombato A, Litzow MR, Tallman MS, Paietta E, Paganin M, Basso G, Gastier-Foster JM, Loh ML, Rabadan R, Van Vlierberghe P, Ferrando AA.

Cancer Discov. 2019 Mar;9(3):436-451. doi: 10.1158/2159-8290.CD-18-1005. Epub 2018 Dec 19.

PMID:
30567843
24.

Loss of plasmacytoid dendritic cell differentiation is highly predictive for post-induction measurable residual disease and inferior outcomes in acute myeloid leukemia.

Xiao W, Goldberg AD, Famulare CA, Devlin SM, Nguyen NT, Sim S, Kabel CC, Patel MA, McGovern EM, Patel A, Schulman J, Dunbar AJ, Epstein-Peterson ZD, Menghrajani KN, Getta BM, Cai SF, Geyer MB, Glass JL, Taylor J, Viny AD, Levine RL, Zhang Y, Giralt SA, Klimek V, Tallman MS, Roshal M.

Haematologica. 2019 Jul;104(7):1378-1387. doi: 10.3324/haematol.2018.203018. Epub 2018 Dec 6.

25.

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib.

Stein EM, DiNardo CD, Fathi AT, Pollyea DA, Stone RM, Altman JK, Roboz GJ, Patel MR, Collins R, Flinn IW, Sekeres MA, Stein AS, Kantarjian HM, Levine RL, Vyas P, MacBeth KJ, Tosolini A, VanOostendorp J, Xu Q, Gupta I, Lila T, Risueno A, Yen KE, Wu B, Attar EC, Tallman MS, de Botton S.

Blood. 2019 Feb 14;133(7):676-687. doi: 10.1182/blood-2018-08-869008. Epub 2018 Dec 3.

26.

Extramedullary acute myeloid leukemia presenting in young adults demonstrates sensitivity to high-dose anthracycline: a subset analysis from ECOG-ACRIN 1900.

Fernandez HF, Sun Z, Litzow MR, Luger SM, Paietta E, Racevskis J, Levine RL, Patel JP, Abdel-Wahab O, Ketterling RP, Dewald GW, Bennett JM, Rowe JM, Lazarus HM, Tallman MS.

Haematologica. 2019 Apr;104(4):e147-e150. doi: 10.3324/haematol.2018.197277. Epub 2018 Nov 22. No abstract available.

27.

A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease.

Litzow MR, Wang XV, Carroll MP, Karp JE, Ketterling RP, Zhang Y, Kaufmann SH, Lazarus HM, Luger SM, Paietta EM, Pratz KW, Tun HW, Altman JK, Broun ER, Rybka WB, Rowe JM, Tallman MS.

Am J Hematol. 2019 Jan;94(1):111-117. doi: 10.1002/ajh.25333. Epub 2018 Nov 15.

PMID:
30370956
28.

Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.

Harding JJ, Lowery MA, Shih AH, Schvartzman JM, Hou S, Famulare C, Patel M, Roshal M, Do RK, Zehir A, You D, Selcuklu SD, Viale A, Tallman MS, Hyman DM, Reznik E, Finley LWS, Papaemmanuil E, Tosolini A, Frattini MG, MacBeth KJ, Liu G, Fan B, Choe S, Wu B, Janjigian YY, Mellinghoff IK, Diaz LA, Levine RL, Abou-Alfa GK, Stein EM, Intlekofer AM.

Cancer Discov. 2018 Dec;8(12):1540-1547. doi: 10.1158/2159-8290.CD-18-0877. Epub 2018 Oct 24.

29.

Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance).

Byrd JC, Ruppert AS, Heerema NA, Halvorson AE, Hoke E, Smith MR, Godwin JE, Couban S, Fehniger TA, Thirman MJ, Tallman MS, Appelbaum FR, Stone RM, Robinson S, Chang JE, Mandrekar SJ, Larson RA.

Blood Adv. 2018 Jul 24;2(14):1705-1718. doi: 10.1182/bloodadvances.2017015396.

30.

LeukeMYC prognostication.

Knorr KLB, Tallman MS.

Leuk Lymphoma. 2019 Jan;60(1):1-2. doi: 10.1080/10428194.2018.1482547. Epub 2018 Jul 6. No abstract available.

PMID:
29979098
31.

Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations.

Intlekofer AM, Shih AH, Wang B, Nazir A, Rustenburg AS, Albanese SK, Patel M, Famulare C, Correa FM, Takemoto N, Durani V, Liu H, Taylor J, Farnoud N, Papaemmanuil E, Cross JR, Tallman MS, Arcila ME, Roshal M, Petsko GA, Wu B, Choe S, Konteatis ZD, Biller SA, Chodera JD, Thompson CB, Levine RL, Stein EM.

Nature. 2018 Jul;559(7712):125-129. doi: 10.1038/s41586-018-0251-7. Epub 2018 Jun 27.

32.

Evolution of a chemosensitive core-binding factor AML into an aggressive leukemia with eosinophilic differentiation.

Xiao W, Yabe M, Offin M, Khattar P, Baik J, Daley RJ, Pappacena JJ, Roshal M, Zhang Y, Tallman MS, Cai SF.

Blood Adv. 2018 Jul 10;2(13):1517-1521. doi: 10.1182/bloodadvances.2018016675. No abstract available.

33.

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.

Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS.

Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25162. [Epub ahead of print]

34.

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML.

Cortes JE, Tallman MS, Schiller GJ, Trone D, Gammon G, Goldberg SL, Perl AE, Marie JP, Martinelli G, Kantarjian HM, Levis MJ.

Blood. 2018 Aug 9;132(6):598-607. doi: 10.1182/blood-2018-01-821629. Epub 2018 Jun 6.

35.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

36.

Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.

Epstein DJ, Seo SK, Huang YT, Park JH, Klimek VM, Berman E, Tallman MS, Frattini MG, Papanicolaou GA.

J Infect. 2018 Sep;77(3):227-234. doi: 10.1016/j.jinf.2018.03.015. Epub 2018 May 7.

PMID:
29746955
37.

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.

Stein EM, Garcia-Manero G, Rizzieri DA, Tibes R, Berdeja JG, Savona MR, Jongen-Lavrenic M, Altman JK, Thomson B, Blakemore SJ, Daigle SR, Waters NJ, Suttle AB, Clawson A, Pollock R, Krivtsov A, Armstrong SA, DiMartino J, Hedrick E, Löwenberg B, Tallman MS.

Blood. 2018 Jun 14;131(24):2661-2669. doi: 10.1182/blood-2017-12-818948. Epub 2018 May 3.

38.

Time to repeal and replace response criteria for acute myeloid leukemia?

Bloomfield CD, Estey E, Pleyer L, Schuh AC, Stein EM, Tallman MS, Wei A.

Blood Rev. 2018 Sep;32(5):416-425. doi: 10.1016/j.blre.2018.03.006. Epub 2018 Mar 27. Review.

39.

Predictive factors of fatal bleeding in acute promyelocytic leukemia.

Mantha S, Tallman MS, Devlin SM, Soff GA.

Thromb Res. 2018 Apr;164 Suppl 1:S98-S102. doi: 10.1016/j.thromres.2018.01.038. Review.

PMID:
29703492
40.

Similar incidence of typhlitis in patients receiving various doses of daunorubicin or idarubicin as induction for acute myeloid leukemia.

Seddon AN, Chaim J, Akin O, Drill E, Michael AG, Adel N, Tallman MS.

Leuk Res. 2018 May;68:48-50. doi: 10.1016/j.leukres.2018.03.004. Epub 2018 Mar 8.

PMID:
29544131
41.

Minimal residual hairy cell leukemia eradication with moxetumomab pasudotox: phase 1 results and long-term follow-up.

Kreitman RJ, Tallman MS, Robak T, Coutre S, Wilson WH, Stetler-Stevenson M, FitzGerald DJ, Santiago L, Gao G, Lanasa MC, Pastan I.

Blood. 2018 May 24;131(21):2331-2334. doi: 10.1182/blood-2017-09-803072. Epub 2018 Feb 27.

42.

Widespread use of measurable residual disease in acute myeloid leukemia practice.

Epstein-Peterson ZD, Devlin SM, Stein EM, Estey E, Tallman MS.

Leuk Res. 2018 Apr;67:92-98. doi: 10.1016/j.leukres.2018.02.006. Epub 2018 Feb 13.

PMID:
29482173
43.

MEF2C Phosphorylation Is Required for Chemotherapy Resistance in Acute Myeloid Leukemia.

Brown FC, Still E, Koche RP, Yim CY, Takao S, Cifani P, Reed C, Gunasekera S, Ficarro SB, Romanienko P, Mark W, McCarthy C, de Stanchina E, Gonen M, Seshan V, Bhola P, O'Donnell C, Spitzer B, Stutzke C, Lavallée VP, Hébert J, Krivtsov AV, Melnick A, Paietta EM, Tallman MS, Letai A, Sauvageau G, Pouliot G, Levine R, Marto JA, Armstrong SA, Kentsis A.

Cancer Discov. 2018 Apr;8(4):478-497. doi: 10.1158/2159-8290.CD-17-1271. Epub 2018 Feb 5.

44.

Pegaspargase-related high-grade hepatotoxicity in a pediatric-inspired adult acute lymphoblastic leukemia regimen does not predict recurrent hepatotoxicity with subsequent doses.

Burke PW, Aldoss I, Lunning MA, Devlin SM, Tallman MS, Pullarkat V, Mohrbacher AM, Douer D.

Leuk Res. 2018 Mar;66:49-56. doi: 10.1016/j.leukres.2017.12.013. Epub 2018 Jan 3.

PMID:
29407583
45.

Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.

Maslak PG, Dao T, Bernal Y, Chanel SM, Zhang R, Frattini M, Rosenblat T, Jurcic JG, Brentjens RJ, Arcila ME, Rampal R, Park JH, Douer D, Katz L, Sarlis N, Tallman MS, Scheinberg DA.

Blood Adv. 2018 Feb 13;2(3):224-234. doi: 10.1182/bloodadvances.2017014175.

46.

Choosing for whom to recommend allogeneic transplantation for acute myeloid leukemia in CR1: a continued, complicated conversation.

Menghrajani KN, Tallman MS.

Blood Adv. 2018 Jan 23;2(2):164. doi: 10.1182/bloodadvances.2017007674. No abstract available.

47.

Disease characteristics and clinical outcomes in patients aged less than 40 with chronic lymphocytic leukemia.

Getta BM, Devlin S, Park JH, Tallman MS, Berman E.

Leuk Res. 2018 Feb;65:80-85. doi: 10.1016/j.leukres.2017.12.008. Epub 2018 Jan 3.

PMID:
29316456
48.

Clinical impact of BAALC expression in high-risk acute promyelocytic leukemia.

Lucena-Araujo AR, Pereira-Martins DA, Koury LC, Franca-Neto PL, Coelho-Silva JL, de Deus Wagatsuma VM, Melo RAM, Bittencourt R, Pagnano K, Pasquini R, Chiattone CS, Fagundes EM, Chauffaille ML, Schrier SL, Tallman MS, Ribeiro RC, Grimwade D, Ganser A, Löwenberg B, Lo-Coco F, Sanz MA, Berliner N, Rego EM.

Blood Adv. 2017 Sep 15;1(21):1807-1814. doi: 10.1182/bloodadvances.2017005926. eCollection 2017 Sep 26.

49.

New therapeutic strategies for high-risk acute myeloid leukemia.

Menghrajani K, Tallman MS.

Curr Opin Hematol. 2018 Mar;25(2):90-94. doi: 10.1097/MOH.0000000000000409. Review.

PMID:
29283906
50.

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia.

Altman JK, Foran JM, Pratz KW, Trone D, Cortes JE, Tallman MS.

Am J Hematol. 2018 Feb;93(2):213-221. doi: 10.1002/ajh.24974. Epub 2017 Dec 4.

Supplemental Content

Loading ...
Support Center